Massimo Martino, Mercedes Gori, Gaetana Porto, Maria Pellicano, Ludovica Santoro, Chiara Verduci, Filippo Antonio Canale, Barbara Loteta, Tiziana Moscato, Caterina Alati, Maria Consuelo Ieracitano, Amelia Cuzzocrea, Maria Altomonte, Maria Teresa Florenzano, Antonella Morabito, Giuseppe Irrera, Virginia Naso, Marta Pugliese, Giuseppe Console, Anna Ferreri, Lucrezia Imbalzano, Giovanni Tripepi, Annalisa Pitino
Multiple myeloma (MM) is the main indication for autologous stem cell transplantation (ASCT). Novel supportive therapies (e.g., granulocyte colony-stimulating factor) have significantly improved post-ASCT-related mortality; however, data on biosimilar pegfilgrastim-bmez (BIO/PEG) in this setting is lacking. This prospective cohort study compared Italian patients with MM who received BIO/PEG post-ASCT with data collected retrospectively from historical control groups from the same center who received either filgrastim-sndz (BIO/G-CSF) or pegfilgrastim (PEG; originator)...
April 20, 2023: Annals of Hematology